The nitric oxide donor molsidomine rescues cardiac function in rats with chronic kidney disease and cardiac dysfunction

Lennart G. Bongartz, Branko Braam, Marianne C. Verhaar, Maarten Jan M. Cramer, Roel Goldschmeding, Carlo A. Gaillard, Paul Steendijk, Pieter A. Doevendans, Jaap A. Joles*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Bongartz LG, Braam B, Verhaar MC, Cramer MJ, Goldschmeding R, Gaillard CA, Steendijk P, Doevendans PA, Joles JA. The nitric oxide donor molsidomine rescues cardiac function in rats with chronic kidney disease and cardiac dysfunction. Am J Physiol Heart Circ Physiol 299: H2037-H2045, 2010. First published September 17, 2010; doi: 10.1152/ajpheart.00400.2010.-We recently developed a rat model of cardiorenal failure that is characterized by severe left ventricular systolic dysfunction (LVSD) and low nitric oxide (NO) production that persisted after temporary low-dose NO synthase inhibition. We hypothesized that LVSD was due to continued low NO availability and might be reversed by supplementing NO. Rats underwent a subtotal nephrectomy and were treated with low-dose NO synthase inhibition with N(omega)-nitro-L-arginine up to week 8. After 3 wk of washout, rats were treated orally with either the long-acting, tolerance-free NO donor molsidomine (Mols) or vehicle (Veh). Cardiac and renal function were measured on weeks 11, 13, and 15. On week 16, LV hemodynamics and pressure-volume relationships were measured invasively, and rats were killed to quantify histological damage. On week 15, blood pressure was mildly reduced and creatinine clearance was increased by Mols (both P <0.05). Mols treatment improved ejection fraction (53 +/- 3% vs. 37 +/- 2% in Veh-treated rats, P <0.001) and stroke volume (324 +/- 33 vs. 255 +/- 15 mu 1 in Veh-treated rats, P <0.05). Rats with Mols treatment had lower end-diastolic pressures (8.5 +/- 1.1 mmHg) than Veh-treated rats (16.3 +/- 3.5 mmHg, P <0.05) and reduced time constants of relaxation (21.9 +/- 1.8 vs. 30.9 +/- 3.3 ms, respectively, P <0.05). The LV end-systolic pressure-volume relationship was shifted to the left in Mols compared with Veh treatment. In summary, in a model of cardiorenal failure with low NO availability, supplementing NO significantly improves cardiac systolic and diastolic function without a major effect on afterload.

Original languageEnglish
Pages (from-to)H2037-H2045
Number of pages9
JournalAmerican Journal of Physiology-Heart and Circulatory Physiology
Volume299
Issue number6
DOIs
Publication statusPublished - 2010

Keywords

  • left ventricular systolic dysfunction
  • rescue therapy
  • hemodynamics
  • SPONTANEOUSLY HYPERTENSIVE-RATS
  • CONGESTIVE-HEART-FAILURE
  • MYOCARDIAL-INFARCTION
  • SYSTOLIC DYSFUNCTION
  • ISOSORBIDE DINITRATE
  • CARDIORENAL SYNDROME
  • DIASTOLIC FUNCTION
  • PRESSURE-OVERLOAD
  • REMNANT KIDNEY
  • NO DONORS

Fingerprint

Dive into the research topics of 'The nitric oxide donor molsidomine rescues cardiac function in rats with chronic kidney disease and cardiac dysfunction'. Together they form a unique fingerprint.

Cite this